BOSTON--(BUSINESS WIRE)--SOLA Biosciences LLC (SOLA) announced the launch of its new website, http://www.sola-bio.com. Headquartered in Boston, SOLA focuses on TapBoost® technology and globally collaborates with pharmaceutical companies and researchers.
In R&D, protein production can present many obstacles such as the inability to produce sufficient quantity of “difficult-to-express” proteins and the high cost of production of biologics. SOLA Biosciences has developed a novel technology called TapBoost®, which assists proper folding of targeted recombinant proteins to improve secretion yields. SOLA’s new website will navigate pharmaceutical companies and researchers to appropriate information: TapBoost® technology, applications in the areas of R&D/manufacturing/therapeutics, and step-by-step licensing procedures.
“TapBoost, conceived and developed by SOLA’s distinguished scientists, could accelerate the pharmaceutical R&D process and greatly decrease the cost of biologics for the patients,” says Dr. Keizo Koya, the founder/CEO of SOLA. “We also anticipate therapeutic applications of TapBoost including new gene therapies for conformational diseases and development of innovative biologics.”
Up to date, SOLA has established ten material transfer agreements with pharmaceutical and biotech companies to evaluate TapBoost® technology for their therapeutic biologics and new target molecules. SOLA is seeking for companies to establish business alliances to accelerate the R&D process for the sake of science and patients.
About SOLA Biosciences
SOLA is a bioscience company, headquartered in Boston, with the goal of improving target proteins production via the breakthrough TapBoost® technology for pharmaceutical companies and researchers around the globe so that we can deliver new therapeutics faster, more efficiently, and at lower overall cost to patients.